Cargando…

Targeting CD47 as a therapeutic strategy: A common bridge in the therapy of COVID-19-related cancers

Macrophages are essential mediators of innate immunity. Non-self-cells resist phagocytosis through the expression of the checkpoint molecule CD47. CD47, as the integrin-associated protein, is overexpressed on tumor and SARS-CoV-2-infected cells as a potential surface biomarker for immune surveillanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zandi, Milad, Shafaati, Maryam, Shenagari, Mohammad, Naziri, Hamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344805/ https://www.ncbi.nlm.nih.gov/pubmed/37456027 http://dx.doi.org/10.1016/j.heliyon.2023.e17959

Ejemplares similares

Monkeypox virus neurological manifestations in comparison to other orthopoxviruses
por: Shafaati, Maryam, et al.
Publicado: (2022)

Mechanisms of immune evasion of monkeypox virus
por: Zandi, Milad, et al.
Publicado: (2023)

Is it possible that arthropods could be an accidental reservoir for the outbreak of mpox virus in 2022?
por: Alizadeh, Ismaeil, et al.
Publicado: (2023)

Monkeypox virus crosstalk with HIV; where do we stand now?
por: Shafaati, Maryam, et al.
Publicado: (2022)

Comments on “Diagnosis of monkeypox virus – An overview”
por: Zandi, Milad, et al.
Publicado: (2023)

Monkeypox virus replication underlying circadian rhythm networks
por: Zandi, Milad, et al.
Publicado: (2023)

Impact of epigenetic mechanisms in re-emerging viruses
por: Shafaati, Maryam, et al.
Publicado: (2023)

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
por: Sun, Jennifer, et al.
Publicado: (2021)

CD47 as a promising therapeutic target in oncology
por: Zhao, Hai, et al.
Publicado: (2022)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
por: Qu, Tailong, et al.
Publicado: (2022)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
por: Chao, Mark P., et al.
Publicado: (2020)

The relevance of the circadian timing system role in patients with HIV/AIDS: a quick glance
por: Shafaati, Maryam, et al.
Publicado: (2023)

Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy
por: Schürch, Christian M., et al.
Publicado: (2019)

CD47 as a Potential Target to Therapy for Infectious Diseases
por: Cham, Lamin B., et al.
Publicado: (2020)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer
por: Yoshida, Kazumichi, et al.
Publicado: (2015)

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Zhang, Wenqi, et al.
Publicado: (2021)

The role of SARS-CoV-2 accessory proteins in immune evasion
por: Zandi, Milad, et al.
Publicado: (2022)

Retracted: Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Markers, Disease
Publicado: (2023)

Role of CD47 in tumor immunity: a potential target for combination therapy
por: Huang, Jing, et al.
Publicado: (2022)

Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma
por: Chen, Jiejian, et al.
Publicado: (2022)

Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma
por: Wu, Hao, et al.
Publicado: (2021)

Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives
por: Ye, Zi-Han, et al.
Publicado: (2023)

CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes
por: Kosaka, Akemi, et al.
Publicado: (2021)

Diabetes Impairs Angiogenesis and Induces Endothelial Cell Senescence by Up-Regulating Thrombospondin-CD47-Dependent Signaling
por: Bitar, Milad S.
Publicado: (2019)

A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
por: Lin, Fangzhen, et al.
Publicado: (2021)

HSP47: A Therapeutic Target in Pulmonary Fibrosis
por: Sakamoto, Noriho, et al.
Publicado: (2023)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
por: Chen, Can, et al.
Publicado: (2022)

EGF Receptor-Targeting Cancer Therapy Using CD47-Engineered Cell-Derived Nanoplatforms
por: Choi, Moon Jung, et al.
Publicado: (2022)

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
por: Xiao, Amy, et al.
Publicado: (2022)

CD47 on artificial structures
por: Schütz, Christian
Publicado: (2015)

Checkpoint CD47 Function On Tumor Metastasis And Immune Therapy
por: Lian, Shu, et al.
Publicado: (2019)

Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells
por: Liu, Liang, et al.
Publicado: (2017)

Antitumor Effects of HPV DNA Vaccine Adjuvanted with Beclin-1 as an Autophagy Inducer in a Mice Model
por: Naziri, Hamed, et al.
Publicado: (2019)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tm4l2u2v6pr5i664651b4h00jc